
Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10
10/1/25